Objective:To systematically characterize false-positive results in newborn screening for congenital hypothyroidism (CH), evaluate their associations with reagent lots, quality control (QC) failures, and testing periods, and establish a workflow-based tracing pathway for false-positive results.Methods:A total of 750 240 newborns screened for CH at the Henan Provincial Newborn Screening Center between January 1 and December 31, 2021 were included. False-positive rates were compared across reagent lots, testing periods, blood-sampling age groups, and seasons. Internal QC stability was evaluated using the distribution of standard deviation index (SDI) values, the number of out-of-control events, and out-of-control rates. Bayesian multivariable regression was performed to quantify the associations of QC failures, blood-sampling age, season, and reagent lot with the risk of false-positive results. A Sankey diagram was used to construct a workflow-based tracing pathway for false-positive results. An independent 2024 screening cohort was used for temporal external validation of the association between QC abnormalities and false-positive results.Results:False-positive rates differed significantly according to blood-sampling age, season, reagent lot, and testing period. Three QC out-of-control events were identified, including one at the low QC level and two at the high QC level. The out-of-control rates for the low-and high-level QC materials were 0.12%(1/856) and 0.23%(2/856), respectively, and 99.88%(855/856) and 99.77%(854/856) of QC measurements were within±3 SDI. A total of 37 049 newborns were screened within the QC out-of-control event windows, of whom 1, 011 had false-positive results. The false-positive rate was significantly higher within than outside these windows 2.73%(1 011/37 049) vs 1.01%(7 209/713 191)(χ
2=959.28,
P<0.001). Bayesian regression showed that QC out-of-control event windows were associated with an increased risk of false-positive results (
OR=2.35, 95%
CI 1.85-2.98), as was winter testing (
OR=2.90, 95%
CI 2.30-3.65), whereas later blood sampling was associated with a lower risk. Workflow-based Sankey tracing showed that approximately 46% of false-positive results were attributable to the analytical phase, with reagent lot-related variation and QC failures being the major contributors. In the independent 2024 temporal validation cohort, the false-positive rate remained higher within QC abnormality event windows than outside these windows [2.50% (488/19 500)vs 1.54%(7 788/504 999),
P<0.001], consistent with the primary cohort.
Conclusion:False-positive results in newborn screening for CH are closely associated with instabilities in the analytical process, particularly quality control abnormalities. Strengthening dynamic, batch-level quality monitoring may facilitate the timely detection of abnormalities and reduce the risk of false-positive results.